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HIV : Human immunodeficiency virus   
HAART   :        Highly active anti retroviral therapy 
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Treatment Panel 3 
AIDS  : Acquired Immunodeficiency syndrome 
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INTRODUCTION    
             AIDS was recognized first in United States in 1981, when pneumocystis jiroveci 
was reported in five healthy homosexual men. The disease was also recognized in male 
and female injection drug abusers. Human immunodeficiency virus (HIV) was isolated in 
1983 from a lymphadenopathy patient. It was clearly established as a causative organism 
for AIDS by 1984. A sensitive enzyme linked immunosorbent assay (elisa) was 
developed in 1985. As a result, an evolution and appreciation of HIV epidemic happened 
first in developed nations and ultimately among the developing nations in world [1]. 
             An important landmark in the management of HIV disease has been the 
availability of new classes of drugs, in 1995-1996, due to the introduction of highly 
active anti retroviral therapy (HAART). This turned HIV infection into a chronic non 
lethal condition. Approximately twenty antiretroviral agents have   been licensed till 
2010, and there has been a speedy approval, based on their effect on the plasma HIV 
RNA levels as well as depending on clinical efficacy. Plasma HIV RNA level is a 
validated accurate marker of HIV activity. 
            The advent of HAART (highly active anti retroviral therapy) has improved the 
quality of life of HIV patients and has prolonged the life of many. Despite these 
spectacular results, a lot of queries remain and a lot of issues are under debate. The 
treatment is with the risk of side effects.  
              Metabolic complications of chronic use of highly active anti retroviral therapy 
include diabetes mellitus, insulin resistance and dyslipidemia. These complications leads 
to an increased risk for cardiovascular morbidity and mortality in HIV infected 
individuals [3]. HIV related lipodystrophy, is a condition with an elevation of plasma 
triglycerides, total cholesterol, sugar levels and it may develop in HIV infected patients 
on HAART. The emergence of these new risk factors that are associated with 
antiretroviral therapy and HIV infection itself represents a new challenge in the 
management [2]. 
              These complications bring a new challenge to the treating physician as he not 
only requires a thorough knowledge of antiretroviral therapy, but he should also deal with 
the problems of chronic illness like diabetes mellitus, dyslipidemia and cardiovascular 
diseases.           
               Crepaldi in 1967 made an interesting observation that a constellation of 
symptoms like obesity, diabetes, dyslipidemia and hypertension occurred in many people. 
This was followed by clustering of these conditions and was termed as “metabolic 
syndrome” by German researchers in the 1970s. Since then this constellation of 
symptoms has been described under a number of guises as “Insulin resistance syndrome”, 
“Syndrome X”, “Plurimetabolic syndrome” and “Metabolic syndrome”. Metabolic 
syndrome is a disease with multiple components as a result of sedentary lifestyle, 
environmental factors, genetic susceptibility all leading to its development. 
                 Several studies have indicated that metabolic syndrome increases the 
occurrence of cardiovascular diseases and type 2 diabetes mellitus. The National 
Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III) has 
identified metabolic syndrome as a cluster of components which increases the risk for 
both cardiovascular disease and type 2 diabetes mellitus. The NCEP-ATP III guideline 
has also stressed the pivotal role of abdominal obesity in the development of metabolic 
syndrome. 
                  The increasing prevalence of metabolic syndrome has important long term 
health implications. We know that every component of the metabolic syndrome is a 
known risk factor for cardiovascular diseases. So, the presence of multiple components 
confers greater risk than that associated with the individual ones. Notwithstanding the 
cardiovascular outcomes, individuals with metabolic syndrome are more susceptible to a 
range of conditions including polycystic ovary syndrome, malignancy, and asthma.  
                 The success of ART in treating HIV infection and its global scaling up, has 
resulted in increased prevalence of diabetes mellitus, insulin resistance, systemic 
hypertension, fat redistribution and dyslipidemia [4]. A range of studies across the globe 
has given a wide prevalence for metabolic syndrome in the HIV population which ranges 
from 11.2% up to 45.4%. The high rates of metabolic syndrome in the HIV-infected 
population and in particular patients on HAART, places it in a cardiovascular diseases 
high-risk category, turning it in to a major public health issue [5-7].  
              The characteristics of dyslipidemia in HIV-infected patients receiving HAART 
include elevated level of total cholesterol (TC), LDL-cholesterol (LDL-c), triglycerides 
(TG), decreased HDL-cholesterol (HDL-c) and increased triglyceride levels.  
               There is limited information on metabolic syndrome prevalence in HIV-infected 
patients receiving HAART worldwide, especially in our country. The prevalence of 
metabolic syndrome and dyslipidemia in resource-limited settings like India has not been 
well studied. Current World Health Organization (WHO) antiretroviral therapy (ART) 
guidelines do not recommend that lipid monitoring should be conducted in patients 
receiving first-line HAART. The objective of the present study was to determine the 
prevalence of metabolic syndrome, dyslipidemia and characteristics of lipid profiles 
among people living with HIV infection receiving first-line HAART ( Lamivudine, 
Zidovudine, Nevirapine ) for more than one year. 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
                  HIV prevalence has increased globally because persons taking antiretroviral 
therapy are having prolonged life. Although fresh HIV infections fell from 33 lakhs in 
2002, to 23 lakhs in 2012, AIDS - connected deaths topped at 23 lakhs in 2005, and fell 
to 16 lakhs by 2012. A supposed 97 lakh people in poor and middle - income nations had 
begun antiretroviral therapy by 2012.  
                  Four groups of HIV-1 prevail and represents different way of spreading events 
from chimpanzees (M, N, and O), and a single group from gorilla (P). Groups P, N and O 
are limited to western Africa. Group M, the causative group of the worldwide HIV 
pandemic, began roughly about 100 years ago and has about nine subtypes: A,B,C,D, 
F,G,H, J, and K.  
                  ‘C’ Subtype occurs mainly in African and Indian regions, and constitutes 
about half of all cases of HIV-1 in 2007 globally [8]. ‘B’ Subtype occurs mainly in 
Western Europe, Americas, and the Australian continent. Recombinant subtypes are 
getting circulated more frequently [8]. The high mutation rate of HIV-1 is due to the error 
- prone action of reverse transcriptase enzyme, and that leads to marked genetic diversity. 
Mean-while HIV-2 is mainly restricted to west Africa and leads to  illness similar to 
HIV-1, but HIV-2 is less transmissible and immunodeficiency progresses more slowly 
[9].  
                  The increasing availability of antiretroviral therapy (ART) has altered the 
global presence of HIV infection markedly [10]. Worldwide prevalence of HIV has 
raised from 310 lakhs in 2002, to 353 lakhs in 2012, due to the persons taking 
antiretroviral therapy (ART) leading a healthier and longer life. The global incidence has 
also dropped mainly due to decrease in heterosexual spread.  
                 HIV is one of the leading causes for the burden of diseases worldwide. 
Globally, HIV was the primary reason for disability-adjusted life years (DALY) for 
persons aged 30–44 years in 2010, and the fifth main reason for all age group [12].  
Roughly half of all deaths in persons on antiretroviral therapy (ART) in high and middle 
income countries are not as a result of AIDS [13]. In a particular study, common etiology 
for non - AIDS related mortality were non -AIDS defining carcinomas (23·5%), heart 
diseases (15·7%), and hepatic diseases (14·1%) [13]. Persons living with HIV have a 50% 
increase in risk for coronary events than do persons not infected with HIV.  Hepatic 
diseases are more regular, predominantly as a result of associated co - infection with 
hepatitis B and C viruses, which also have same way of spread as that of HIV. 
      
Pathophysiology  
               The important target of Human immune deficiency virus activity is CD4 helper 
T lymphocytes; which enters through CD4 interactions and the chemokine  coreceptors, 
CCR5 or CXCR4. Other cells which bears these are also affected, which includes resting 
CD4 T cells, monocytes, macrophages, and dendritic cells. In renal epithelial cells and 
astrocytes , infection of cells can also happen without the dependence of CD4. It 
subsequently plays a central role in development of HIV-associated nephropathy 
(connected to epithelial cells) and neurocognitive disorders (connected to astrocytes). A 
series of host protein interactions with HIV DNA and HIV protein happens, which either 
initiates or stops replication in specific cell types. 
  
 
                       HIV gets transmitted through mucosal membrane which generally is 
established by one founder virus. The special phenotypic properties consist of usage of 
CCR5 rather than CXR4 for access,[14] increased dendritic cell interaction, and 
interferon-α  resistance [15]. Transmission of the founder virus is trailed by a tremendous 
raise in HIV multiplication followed by a characteristic generation of inflammatory 
cytokines and chemokines. This is in firm contrast to the initial mild reaction to other 
chronic viral infections like hepatitis B or hepatitis C [16].  
                  Neutralizing antibodies roughly arise three months after HIV transmission. 
These help in the selection of viral escape mutants [17, 18]. These broad neutralizing 
antibodies are exemplified by increased frequency of somatic mutations which takes 
many years to develop [19]. These antibodies are of no help to the patient due to the 
emergence of viral escape mutants [20]. The synthesis of these neutralizing antibodies 
with the development of immunogen design technique is an important part of vaccine 
research tasks [21]. The inbuilt immunological response to HIV is primarily enforced by 
natural killer cells, which is also very pivotal for virus control. The emergence of viral 
escape mutants restricts the antiviral properties of natural killer cells [22]. 
Immune malfunction 
        The characteristic property of HIV infection is the gradual and advancing decrease 
in CD4 T cells as a result of increased destruction and markedly decreased synthesis. 
CD4 T cells are terminated by infection per se directly [23], sinister results of syncytial 
formation, proliferation, immune reaction, and aging. In the beginning stages of  
infection, a temporary decrease in circulating CD4 T cells is trailed by regaining to near 
normalization, which is followed by a slow decrease of about 50–100 cells per microlitre 
( figure below). 
 
                The crucial outcome on T-cell homoeostasis begins first in the gastrointestinal 
tract, which has a gross exhaustion of active CD4 T cells with very mild regaining 
following antiretroviral therapy [24]. Also intense changes in T-cell elements occur, 
which includes substantial loss of T-helper-17 cells. In addition to these, there is also loss 
of total CD4 T cells [25] and mucosal - related T cells invariant, which are important for 
protection against bacteria [26]. The enterocyte apoptosis together with intense decrease 
of lymphoid cells in the gastrointestinal tract and increased gastrointestinal tract 
permeability, leads to raised blood levels of bacterial components like 
lipopolysaccharides (lps) [27].   And lastly, loss of the fibroblastic reticular cell network, 
limited  response  to the T-cell survival factor IL- 7 in the lymphoid tissue and aggravated 
collagen deposition,  all these leads on to decrease of both CD4 - naive and CD8 - naive 
T cells [28]. 
Immune reactivation 
             HIV infection is symbolized by a significant raise in the activation of immune 
system, and that has both the innate and adaptive immune systems, and defects in 
coagulation and clotting [29]. The likely effects of HIV as a ligand for the TLR7 and 
TLR 8 acts as a driver for immune activation which is implied on plasmacytoid dendritic 
cells, and it leads to the synthesis of interferon-α;[30]  translocation of organisms, with 
lipopolysaccharide (lps) acting as a effective stimulant of TLR4 resulting in the synthesis 
of pro-inflammatory cytokines like tumour necrosis factor α (TNFα) and interleukin 6(IL 
6);[27] co - infection with  cytomegalovirus (CMV) which stimulate significant increase 
of cytomegalovirus induced specific T cells;[31] and a decreased  ratio of T-helper-17 
and regulatory T cells, particularly in the digestive tract [25]. 
                  Observation of increased immune activation or residual inflammation 
prevails, also in HIV patients on antiretroviral therapy with sufficient CD4 T-cell revival. 
Presence of increased immune activation and  residual inflammation in persons on 
antiretroviral therapy have been significantly related to raised deaths [32], cardiac 
ailments [33], carcinomas [34], liver dysfunction [35] and neurological involvement [36]. 
Intense antiretroviral therapy in HIV patients and virological repression with the 
inclusion of raltegravir an integrase inhibitor decreases T-cell operation in roughly one 
third of partakers [37]. Such data indicate that a small level HIV multiplication 
contributes to continuous inflammation.  
                     Despite several research papers and studies have indicated the relation 
between adverse clinical events and different biomarkers of   inflammation, a solid cause 
and effect has been difficult to establish. Various medications which are used for other 
diseases and ailments (eg, statins, acetylsalicylic acid, hydroxychloroquine and 
angiotensin - converting enzyme inhibitors) have the ability to decrease the inflammation 
due to the above said factors [38]. Randomized controlled trials are necessary to 
substantiate that decreasing inflammation in HIV patients with virological repression on 
antiretroviral therapy will have a considerable beneficial outcome [39]. 
                 Not dwelling on the infective manifestations of HIV, in the forth coming pages 
we will elaborate on the non infective manifestations. 
Non infective manifestations of HIV – AIDS 
                The manifestations of the disease are mainly due to the direct result of 
chronicity of the infection, while the remaining factors like senescence, ongoing 
inflammatory process, antiretroviral therapy etc also play an important role. Treating 
doctors should look in to the HIV patient's latest CD4 lymphocyte count and assess 
management.  
Neuro - psychiatric manifestations 
                         Researchers describe a range of dysfunctions as a result of HIV - 
associated inflammation and neurotoxicity, specifically in persons with previous 
decreased CD4 lymphocyte levels [40-42]. Neurological dysfunction varies from minimal 
(asymptomatic cognitive disturbance) to intense (HIV associated dementia). To sum up, 
these are labeled as HIV – related neurocognitive diseases. Evidence also indicates that 
neurodegenerative diseases, like early - onset Alzheimers, have increased significantly in 
persons with HIV infection, also in those persons whose disease activity is very minimal 
[43-44]. It generally involves the peripheral nervous system as distal peripheral sensory 
polyneuropathy or as radicular involvement. The usage of antiretroviral medications and 
other associated conditions like diabetes mellitus may exacerbate the neurological 
complications.  
Cardiovascular complications                      
                         Several studies have demonstrated that increased rates of atherosclerosis 
and coronary events in persons with HIV infection [45-46]. HIV seems to raise the 
occurrence of cardiovascular ailments independently through chronic vascular 
inflammation, elevated cytokine levels, and endothelial dysfunction [47]. Infection 
related vascular events might be added with deleterious effects of lipid and metabolic 
changes due to infection per se as well as antiretroviral use. Currently, coronary event 
risk and dyslipidemia assessment in these persons are done with the help of the NCEP-
ATP3 guidelines.  
                    Although research studies are estimating the beneficial effects of replacing 
antiretroviral drugs [48]; the development of new side effects and increase in viral count 
must be estimated against older options like administering statins, etc. Rarer infection - 
related complications like cardiomyopathy, pericarditis and myocarditis are described, 
but their occurrence has reduced as a result of combination antiretroviral therapy. This 
reduction of these complications is partly due to a decrease in occurrence of opportunistic 
infections. 
Pulmonary complications 
                         The occurrence of pulmonary arterial hypertension (PAH), chronic 
obstructive pulmonary disease (COPD), and lung carcinomas have stayed static or in 
raise among these persons over the last few years [49-52]. Even though the 
etiopathogenesis of HIV - related pulmonary arterial hypertension (PAH) is mainly not 
known, the pathologic vascular changes and clinical pictures are similar to those of HIV 
non infected persons.  
                        Some studies have suggested that HIV increases emphysema – related 
events in smokers, guiding on to higher rates and sooner occurrence of chronic 
obstructive pulmonary disease (COPD) [51]. HIV also increases the occurrence of lung 
carcinomas, which are not dependent on smoking [52].  
Gastrointestinal and Hepatic Systems 
                         Antiretroviral use and elevated triglyceride levels are one of the main 
causes of HIV- associated pancreatitis, rather than opportunistic infections. Acalculous 
cholecystitis is also related to these infections. Chronic parenchymal liver diseases due to 
viral or non viral etiologies has lead to increased morbidity and mortality in HIV infected 
patients; patients should be ideally screened for hepatitis during HIV diagnosis [53,54].   
                           Those persons with hepatitis C co - infection, nonalcoholic fatty liver 
disease (NAFLD) is also frequently occurring as a complication of HIV. Nonalcoholic 
fatty liver disease (NAFLD) is also related with numerous factors such as insulin 
resistance, dyslipidemia, visceral adiposity and mitochondrial toxicity [55, 56]. Newly 
developed biomarker and metabolic panels and imaging utilities like transient 
elastography are studied, since inflammatory biomarkers are more often within normal 
limits and sonography is not sensitive.  
                        HIV affects GI motility by involving the autonomic nervous system and 
also by directly invading intestinal cell populations causing HIV associated enteropathy. 
Increased incidence of inflammatory bowel diseases have been documented in these 
population, for which the etiology is not clear.  
Renal complications 
                   The range and development of HIV - related renal disease has transformed. 
Acute and subacute complications related to antiretroviral therapy (ART), like 
nephrolithiasis due to protease inhibitor and renal toxicity from tenofovir usage, 
continues to happen. However the occurrence of end - stage renal disease (ESRD) due to 
HIV - associated nephropathy [HIVAN]  have plateaued [57], but other risk factors such 
as diabetes mellitus, systemic hypertension  and hepatitis C are leading as a causative 
factor for chronic renal disease in these patients.  
                             HIV associated nephropathy [HIVAN] has to be thought, in these persons 
with albuminuria and gradually declining kidney function; the diagnosis for which 
requires renal biopsy.  
Metabolic and Endocrine Complications 
                  There are imbalances in the way body handles the metabolism of 
carbohydrates, lipids, protein in these patients and the etiologies are thought to be multi 
factorial. Despite these, several studies have indicated that insulin resistance, diabetes 
mellitus, dyslipidemia, and lipodystrophy are a result of antiretroviral therapy (ART) 
[58]. There exists complicated interaction between these persons and their own risk 
factors, drug effects, and infection (HIV itself leads on to chronic inflammatory changes, 
immune system reactivation)    that explains these complications.  
Other endocrine complications 
                Several studies have indicated that hypothalamo–pituitary-adrenal disorders 
and gonadal disorders in these persons associated with HIV infection. The involvement 
of central nervous system resulting in adrenal deficiency and gonadal dysfunction due to 
the involvement of hypothalamus and pituitary gland has been reported. Adrenal 
deficiency is always minimal and it is due to the direct adrenal infection of HIV, wide 
spread opportunistic infections, cancers, or drug usage. Testosterone hormone 
insufficiency and irregular menses is rampant in these individuals with enhanced HIV 
infection or AIDS [59]. 
Other complications 
                  Studies have estimated a 3 to 6 fold increase in risk of decreased bone mineral 
density in HIV infected patients [60]. Some studies have reported that antiretroviral 
therapy is related with osteopenia and osteoporosis. But we also have to keep in mind  
other associated  factors such as body weight, CD4 lymphocyte count of the patient, 
menopausal status, drug  usage in particular steroids. HIV infected patients are vulnerable 
to osteonecrosis and osteomalacia with osteonecrosis manifesting typically as arthralgia 
and stiff joints especially in the shoulder girdle and hip girdle.  
                 Older nucleoside analogues may cause myopathy, but it is of less occurrence 
due to the presence of newer alternative agents. HIV infection also causes an autoimmune 
- induced myopathy. HIV infected patients on antiretrovirals (particularly protease 
inhibitors) should be carefully considered for the co administration of commonly 
prescribed drugs such as statins, calcium channel blockers, antiepileptics due to the risk 
of myopathy, rhabdomyolysis, and possibly HIV treatment failure. 
HAART (highly active antiretroviral therapy) 
                  Since the advent and usage of Zidovudine (AZT) in 1987, there has been 
tremendous advance in antiretroviral therapy. Due to the introduction of highly active 
antiretroviral therapy (HAART) for infected persons, HIV-1 infection is controllable as a 
chronic disease on those achieving virological suppression and in those who have access 
to medication. HAART, or highly active antiretroviral therapy, is basically nothing but 
different mixture of antiretroviral medicines with distinct mechanisms of action in 
treating HIV. This mixture or fusion of drugs is the characteristic nature of HAART. 
                 Increased mortality among AIDS patients was reduced considerably in the 
HAART period (image below). An important point to note is the difference in mortality 
between patients with AIDS and patients without AIDS, and it is five times higher in the 
former. The threshold of CD4+ cell count for HAART introduction were increased lately 
from 350 to 500 cells / ml in the United States meanwhile in our country, it was raised 
from 200 to 350 cells / ml. What these new guidelines infer is a considerable raise in the 
volume of persons who may need ART and also an early HIV evaluation [62]. 
                  Above diagram denotes the differences in the survival of people infected with 
HIV who were started on early or late HAART. It indicates that more aggressive the 
treatment are, more effective the results and survival of the patients. Despite the 
improved survival rate of persons with HIV infection it is not touching the curve of 
uninfected people [63]. 
                   HAART offers efficient therapeutic options for these persons, who are 
treatment-naive or treatment-experienced. Six groups of antiretroviral agents are 
available to patients, which are: 
1) Nucleoside reverse transcriptase inhibitors (NRTIs) 
2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
3) Protease inhibitors (PIs) 
4) Integrase inhibitors (INSTIs) 
5) Fusion inhibitors (FIs) 
6) Chemokine receptor antagonists (CCR5 antagonists) 
               Each group of drugs affects various steps in the life cycle of virus as they come 
in contact with a CD4+ T lymphocyte or other equivocal cells [61]. 
 
Nucleoside Reverse Transcriptase Inhibitors 
               One of the initial group of medication used for the management of HIV 
infection were the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). They 
are less potent against HIV than non - nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), and integrase strand-transfer inhibitors (INSTIs). 
The NRTIs displays its action over both HIV-1 and HIV-2 [64]. 
There are eight medications in the NRTI group which follows: 
 Abacavir                                      Didanosine  
 Emtricitabine                               Lamivudine  
 Stavudine                                    Tenofovir   
 Zalcitabine                                   Zidovudine   
Mechanism of action 
                  NRTIs act through competitive retardation of reverse transcriptase enzyme 
and results in abrupt end of the DNA chain leading to interruption of the HIV replication 
cycle [65]. The purine and pyrimidine nucleoside gets incorporated in to the 3’ end of the 
growing chain of viral genome. This process called as proviral DNA chain elongation 
occurs prior to genome insertion. NRTIs are biochemically identical to the purines and 
pyrimidines and becomes inserted instead of them in to the proviral DNA which results in 
abrupt end of proviral DNA elongation. Emtricitabine, Tenofovir, Lamivudine also 
exhibits agility against hepatitis B virus (HBV) and are usually incorporated into 
antiretroviral regimens for HBV and HIV coinfection. 
Adverse events 
                 NRTI class can cause mitochondrial toxicities like lactic acidosis, hepatic 
steatosis, lipoatrophy, pancreatitis, peripheral neuropathy [66]. NRTI binds to human 
mitochondrial DNA polymerase gamma enzyme and impairs cellular respiration leading 
to mitochondrial toxicities. As a result, anaerobic metabolism starts as it shifts from 
aerobic process, culminating in mitochondrial toxicities. The ability of the NRTI class to 
closely bind with mitochondrial DNA polymerase gamma enzyme is indicative of the 
complications, the drug is capable of and it differs with individual drugs. Zalcitabine 
being the drug with maximum affinity and complications and  tenofovir the least [67,68]. 
             Side effect profile of individual drugs vary and include myopathy, pancytopenia 
due to bone marrow suppression and headache with zidovudine therapy and an allergic  
hypersensitivity type of reaction with abacavir [66]. Abacavir and didanosine are related 
with adverse risk for cardiac ailments. ART initiation sometimes causes increased bone 
turnover and bone loss from the hip and spine. 
Non-nucleoside Reverse Transcriptase Inhibitors 
              Nevirapine was the first approved Nonnucleoside reverse transcriptase inhibitor 
(NNRTIs) that was used worldwide. NNRTIs are effective drugs against HIV-1, in 
particular Efavirenz provides the most potent and considerable viral inhibition among the 
NNRTIs [69].  
The following are the individual drugs in this group. 
First - generation NNRTIs 1) delavirdine        Second - generation NNRTIs        
                                          2) efavirenz                                       1) etravirine 
                                          3) nevirapine                                     2) rilpivirine                                                           
             Both generations of NNRTIs have the same pharmacodynamics and mechanism 
of action. All first - generation NNRTIs have same resistance    profiles, whereas second 
– generation NNRTIs show a more distinct resistance pattern. But their other 
pharmacokinetic qualities and side effect events have significant variations. 
Mechanism of action 
            There are two subunits, p66 and p51 in HIV reverse transcriptase which is a dimer 
[70]. NNRTIs bind the p66 subunit of this enzyme at a hydrophobic   end which is distant 
from the agile end of this enzyme. A conformational change due to this noncompetitive 
binding in the enzyme changes the agile end and curbs the action of the enzyme [70]. 
            Etravirine a highly flexible molecule varies from other NNRTIs (first generation) 
in its capacity to fix and act at this end, in spite of the mutations which limits the 
effectiveness of other agents. It also rotates within the binding site which allows multiple 
binding conformations. 
Adverse events 
                  Studies have reported that rashes always arise during the initial few weeks of 
NNRTI treatment. It is also the most frequent side effect occurring with these groups of 
drugs [66], and peculiarly they resolve with prolonged medication [66, 71]. All NNRTIs 
causes some degree of hepatotoxicity except etravirine [72]. Efavirenz and delavirdine 
can increase the level of transaminases, while nevirapine may induce life threatening 
hepatic toxicity and failure, such as liver necrosis when CD4 counts exceeds 250 cells / 
microlitre [73]. 
                   Efavirenz is different in the NNRTI group, as it causes neurological effects 
like sleeplessness, confusion, hallucinations, day dreaming, near syncope. After several 
weeks of efavirenz therapy tolerance to CNS adverse effects occurs. Not taking food 
during drug intake and bedtime intake of medications can limit the severity of side 
effects. In a small number of patients CNS effects may persist, which needs medication 
withdrawal [66]. 
Protease Inhibitors:  
                HIV protease inhibitors (PIs) are an inherent component of management of 
HIV infection [66].  
Following are the eight compounds which are available: 
           Atazanavir                                                               Darunavir  
Fosamprenavir                                                         Indinavir  
Lopinavir/ritonavir                                                   Nelfinavir  
Saquinavir                                                                Tipranavir  
       Though all these protease inhibitors (PIs) display identical mechanism of action, 
there are some characteristic variations in pharmacokinetics, drug efficacy and side effect 
patterns. 
Mechanism of action 
                Late in the viral life cycle of HIV, an aspartic acid protein called HIV protease 
which has 99 amino acids is the culprit for the growth of virus particles. After viral 
budding from an infected cell, this enzyme protease splits separate proteins into small 
subunits from the polypeptide precursors for viral capsid formation. These drugs act as 
competitive inhibitors, which on binding to protease enzyme, prevents splitting of 
polypeptides [74]. 
 
 
 Adverse events 
               Metabolic complications like dyslipidemia, lipodystrophy, insulin resistance and 
gastrointestinal side effects like diarrhea, nausea, vomiting are the common adverse 
events associated with protease inhibitors. Protease inhibitors may lead on to the 
development of dyslipidemia in up to two third of patients and may warrant beginning of 
statins and other therapies. 
              Studies have indicated that Indinavir has the maximum ability for altered 
carbohydrate metabolism. Some changes in the metabolism are noted with nelfinavir, 
tipranavir, lopinavir and fosamprenavir. Atazanavir, darunavir, and saquinavir seems to 
have decreased efficacy on insulin sensitivity [75]. 
               Fat redistribution happens in roughly half of these persons, who are getting 
protease inhibitors (PIs) along with nucleoside reverse transcriptase inhibitors (NRTIs) 
[76]. Fat deposition (raised ventral cervical and dorsal fat, raised chest fat, truncal 
obesity) or loss of fat (fat loss in cheeks, buttocks, upper, and lower limbs) are the 
common manifestations. Fat accumulation and fat loss are considered independent 
entities. Recent data demonstrates that fat accumulation happens when both protease 
inhibitor (PIs) – and NNRTIs are included in the regimens rather than protease inhibitors 
alone. 
                 Atazanavir and indinavir are associated with asymptomatic hyperbilirubinemia 
but when SGOT and SGPT levels are normal, it does not require discontinuation of 
therapy. Renal stones happen more frequently with indinavir and far less frequently with 
atazanavir [66]. Some persons who are getting atazanavir may sometimes acquire 
conduction defects in the heart like AV blocks and bundle branch blocks. Other protease 
inhibitors (ritonavir, lopinavir, nelfinavir) are less commonly associated with these.  
Integrase Strand-Transfer Inhibitors 
                       The description of HIV integrase’s crystal structure led to the identification 
of novel inhibitors. Since there is no homolog for HIV integrase in humans, their usage is 
anticipated to lead on to meager side effect profile [77, 78]. With the FDA sanctioning 
raltegravir, it became the premier integrase strand-transfer inhibitor (INSTI) valid for 
usage. 
                         Elvitegravir  is one another integrase inhibitor that is used in combination 
with an HIV protease inhibitor (atazanavir, fosamprenavir, tipranavir, lopinavir, 
darunavir) and coadministered with ritonavir plus other antiretroviral drugs. Dolutegravir 
was also sanctioned by the FDA in August 2013.  
Mechanism of action 
               Proviral integration that is movement and linking of proviral DNA to host-cell 
chromosomes, and it allows the synthesis of viral proteins which involve 2 catalytic 
reactions as follows: 
 There will be 3'-processing in the host cells, such that the viral strands are 
prepared to get itself attached to viral DNA. 
 Transposition of strands through which viral DNA is linked to host cell DNA and 
this is an important step in viral replication. These agents competitively arrest the 
transposition of strands by holding metallic ions in the agile site [79]. 
Adverse events 
               Gastrointestinal side effects like nausea, diarrhea and headache are the frequent 
side effect events noted in research studies of raltegravir. Laboratory abnormalities like 
three to four times the raise in levels of SGOT, SGPT, lipid profile, and amylase levels 
were observed in phase III studies. 
               Some studies have shown very rare occurrences of myopathy and 
rhabdomyolysis along with two to four times the elevations of creatine kinase levels [80]. 
These studies have also shown a very rare occurrence of cancers with a relative risk of 
malignancy of 1.2 cases per 100 patient-years. Since it has been documented in phase II 
and phase III studies of raltegravir, it warrants regular monitoring [80].  
Fusion Inhibitors 
                  Fusion inhibitors (FIs) are different in that they target the HIV replication 
cycle extracellularly and were the premier group of antiretroviral medications to do so. 
Their unique action provides added options for highly therapy nonresponsive persons. 
Their use in the treatment of HIV is often restricted, and right now enfuvirtide  is the only 
available drug in this group. 
Mechanism of action 
                 These groups of drug perform to interrupt the fusion of virus to the target cell 
which may be a CD4 cell or other related cells. They act by interrupting the fusion 
pathway and it binds to the glycoprotein 41 (gp41).  So what this means is that HR1 and 
HR2 do not bend adequately, and so halting and blocking the morphological change of 
gp41. This makes the last step in the fusion pathway incomplete [81, 82]. 
Adverse events 
                Since enfuvirtide is a parenteral injection, those persons getting these drugs, at 
times sense injection - site adverse events which leads on to patients discontinuing drugs. 
Adverse event consists of skin nodules, ecchymosis, reddening of skin, itching and pain. 
Sometimes very rare unwanted events include diarrhea, nausea, fatigue and 
hypersensitivity reactions. Some studies have reported that these drugs may be related 
with a raised risk for bacterial pneumonias. 
Chemokine Receptor Antagonists 
               These are novel class of antiretroviral agents in which the first drug maraviroc 
was approved by the FDA in 2007. Along with fusion inhibitors (FIs) it is grouped as 
general antiretroviral treatment class of HIV-entry inhibitors. 
Mechanism of action 
               The process through which HIV and CD4 cells attaches itself and finally merges 
is a complicating process. It all commences with the fusion of the glycoprotein 120 
protein on the surface of the virus to the CD4 receptor. Such attachment leads to a 
morphological variation, which exposes the V3 loop. This V3 loop then bonds with the 
CCR5 or CXCR4 co receptor, culminating in fusion of the cell membranes. In a nut shell, 
Maraviroc is a tiny element that specifically and cohesively attaches with the CCR5 co 
receptor which is a chemokine co receptor, blocking and inhibiting fusion of the cellular 
membranes [83, 84]. 
Adverse events 
                     Adverse events that are reported in various papers show that persistent 
cough, pulmonary infections, fever, rashes, myalgia, arthralgia, abdominal pain and 
dizziness. Dose-limiting effect is postural hypotension which was found out initially 
during the testing of maraviroc. In pooled analysis, when the dose of maraviroc exceeds 
600 mg/day, postural hypotension occurs. Extreme caution is necessary when maraviroc 
is given to any persons who are prone to hepatic impairment since severe hepatotoxicity 
has been reported [83]. 
 
 
 
 
 
Metabolic syndrome and cardiovascular diseases 
      
                     The one that acts as a pivot among various parts of metabolic syndrome is 
insulin resistance. It has firm relationship with obesity particularly its truncal or 
peripheral component. The current prevalence of obesity is primarily acquired, with 
changes in dietary pattern. The world has changed from food deficiency to that of excess 
with sedentary life style. Excess fat, if it is present inside fat cells or adipocytes, it usually 
does not lead on to ill health. Many research studies have shown that lipid is deposited 
mainly in fat cells or adipocytes due to the effect of leptin. So leptin resistance or 
deficiency causes tissue deposition of lipids. The visceral or central component of ectopic 
distribution of fat causes insulin resistance.  
                Genetic factors also play an important role in human fat distribution resulting in 
variations of intra-abdominal fat mass. The epidemiological evidence which links truncal 
obesity with type 2 diabetes mellitus and various components of metabolic syndrome is 
undoubtful.  
                        There are good amount of research studies, which evidently says that 
raised level of free fatty acid is the main etiological factor for insulin resistance. There is 
retention of triglycerides within the cells, and to be specific of end products of fatty acid 
metabolism like fatty acid CoA’s, diacylglycerol, and ceramides in the cells that are 
responsive to insulin. This process leads on to interference and disturbance of signaling 
of insulin above paving way for defects in insulin signaling. In striated muscles, the 
above process makes the transportation of GLUT 4 to the cell surface defective. As a 
result there is opposition to insulin mediated glucose uptake in to the cells. Also in 
hepatic cells, there is opposition to insulin stimulated hepatic glucose production 
suppression.   
                         Raised plasma free fatty acid levels also leads on to decreased insulin 
release by pancreatic beta cells. There is growing proof that TNF alpha may play its part 
in the pathogenesis of insulin resistance. 
                         Large number of studies have shown various ways through which 
systemic hypertension develops in metabolic syndrome. 1) Leptin through sympathetic 
activation. 2) Endothelial dysfunction due to blunting of the vasodilators like  nitric 
oxide, and raised synthesis of vasoconstrictors such as angiotensin II, endothelin-1. 3) 
Renal sodium retention as a result of hyperinsulinaemia. 
                         Increased free fatty acid delivery to liver causes raised production of 
triglycerides and indirectly to raised secretions of VLDL apoB-100 from liver. There is 
insulin resistance in the liver, which infers that insulin is not inhibiting both the 
production of triglycerides and the secretions of VLDL apoB-100. The activity of 
cholesterol ester transfer protein is raised as a result of elevated VLDL which is rich in 
triglyceride. As a result there is raised movement of triglycerides from VLDL to HDL 
and LDL instead of cholesterol. Hepatic lipase hydrolyses the triglyceride causing  
        (a) Raised removal of HDL cholesterol from blood  
        (b) Accumulation of small, dense, largely atherogenic LDL substances.     
 
 
Thus, the highly “atherogenic dyslipidemia” is characterized by: 
 -  Raised triglyceride levels 
 -  Low levels of HDL cholesterol in the blood 
 -  Normal levels of LDL cholesterol, but they are tiny, dense, highly atherogenic LDL 
substances.  
                     South Asian populations in particular Indians, show high body fat and lower 
muscle mass at non-obese body mass index and so there is selective increase in truncal 
obesity.  So, at a BMI of 24 Kg / m2, 75% of such individuals display insulin resistance. 
This explains why we have increased risk of diabetes and CVD. There is also evidence 
that such tendency to central deposition of fat is present in South Asians since childhood 
[93]. 
    
The above diagram illustrates, how different components of metabolic syndrome leads on 
to atherosclerosis, plaque thrombosis and cardiovascular events.  
 
ANALYSIS              
              With these background facts, we shall now focus on the prevalence of metabolic 
syndrome and dyslipidemia in HAART patients. In the forthcoming pages, we will 
analyze relevant studies on this subject done elsewhere, before dissecting our own study. 
So, let us analyze few studies. 
a) Prevalence of Metabolic Syndrome Among HIV Patients, published in 2002, 
American diabetes association paper  
                      In this study the prevalence of the metabolic syndrome was evaluated in 
this big cohort of HIV persons on HAART. A total of 553 patients were recruited (321 
men, 232 women) with a mean age of the patients being 37.1 ± 7.3 years (range 20–61) 
were studied. The study was done with metabolic syndrome defined according to NCEP-
ATP3 criteria.  
                     Among HIV patients on HAART, 133/533 (24.0%) patients had elevated 
fasting glucose or were on anti diabetes medication usage, 234/533 (42.3%) patients had 
systemic hypertension, 328/533 (59.3%) had elevated triglyceride levels, 209/533 
(37.8%) patients had central obesity and 290/533 (52.4%) patients had low HDL. Single 
component of metabolic syndrome was seen in 108/533 (19.5%) patients, two 
components in 95/533 (17.2%), three components in 146/533 (26.4%), four components 
in 67/533 (12.1%), and five components in 38/533 (6.9%). Of these, no component of 
metabolic syndrome were seen in 99/533 (17.9%). Metabolic syndrome (at least three 
risk factors) was found in 251 patients, leading to a prevalence of 45.4%.  
                           This prevalence was higher than that observed in subjects older than 60 
years and more than twofold that was documented lately by Ford et al in the general 
population [86]. The difference in the prevalence of metabolic syndrome between the 
general population and this cohort of HIV patients on HAART appears to be very 
remarkable. Though there are some drawbacks like comparing Italian HIV patients with 
American general population with different genetic trait, the association seems significant 
[85]. 
b) Prevalence of metabolic syndrome in HIV - affected patients on HAART from 
the South-West region of Cameroon 
                    In this cross-sectional study done in Cameroon, 173 untreated and treated 
HIV-infected out-patients (aged 18–70 years) managed at the Buea and Limbe Regional 
Hospitals and 50 seronegative individuals (controls) were recruited and studied after 
obtaining their consent. After obtaining ethical approval for this study, metabolic 
syndrome prevalence was examined using the NCEP - ATPIII criteria.  
Results and discussion 
                     The prevalence of Metabolic syndrome among the HIV patients was 15.6% 
(27/173) and 8% (4/50) among the controls and the difference was significant 
(p = 0.022). Of these metabolic syndrome was more prevalent in HIV-infected patients 
on HAART than in ART-naive patients and seronegative individuals. The patients on 
first-line drugs showed the highest prevalence (15/62; 24.2%) followed by the ART-naïve 
group of HIV patients (7/61; 11.5%) and the lowest prevalence was among the patients 
on protease inhibitors {PIs} (5/50; 10%). Overall, the prevalence of metabolic syndrome 
was significantly higher (p = 0.003) in females (28/153; 18.3%) than in males (3/70; 
4.3%). Patients on the following drug combinations Lamivudine / Stavudine / Nevirapine 
had the highest prevalence of metabolic syndrome (50%) [87]. 
c) Prevalence of lipodystrophy and metabolic syndrome in HIV positive patients 
on HAART in South West Ethiopia  
                This study done in Ethiopia documented several vital information and factors 
related with metabolic disorders among these patients. The prevalence of metabolic 
Syndrome was documented as 21.1%. This study also states that an important risk factor 
for the development of metabolic syndrome was the duration of HAART and female sex. 
The prevalence of dyslipidemia as per this study was 48.2%.  
                In this study the prevalence of metabolic syndrome was 21.1%, this finding was 
less than another Italian study [88] which put the figures at 25.4 %. The main reason 
attributed was that the Italian study was done in HIV patients, who were taking HAART 
for more than 6 months; but in this study all HIV patients who were taking HAART were 
included. The result of total duration of HAART on metabolic syndrome is also recorded 
elsewhere [89].  
d) Prevalence of Metabolic Syndrome in HIV Patients Receiving HAART Using 
IDF and NCEP- ATP3 criteria with insulin resistance, disturbed body fat 
compartmentalization, elevated C-reactive protein, and hypo adiponectinemia. 
Katherine Samaras, MBBS, FRACP, PHD, Handan Wand, PHD. ADA journal 
2007. 
                    About 788 HIV - affected adults were included at 32 different places, which 
being an international cross-sectional study. Metabolic syndrome prevalence was 
examined using  IDF and NCEP-ATPIII criteria, in relation to body morphology  (whole  
body dual - energy X-ray absorptiometry and abdominal computed tomography imaging), 
leptin, adiponectin, and C-reactive protein (CRP), lipids, glycemic parameters, insulin 
resistance. 
                      The prevalence of metabolic syndrome was 14% by IDF criteria and 18% 
by NCEP-ATPIII criteria; there was only moderate concordance. Roughly half of these 
patients have two out of five components of metabolic syndrome as a result they were not 
labeled as metabolic syndrome. In particular, their waist circumferences did not fit to the 
metabolic syndrome range. In this context, the waist circumference criteria differ for 
westerners and south Asians and the cut off is decreased. Those receiving protease 
inhibitors were found to have more presence of metabolic syndrome, which is in contrast 
to the previous Cameroon study. Type 2 diabetes mellitus presence was five to nine fold 
more in patients with metabolic syndrome, which is a very significant value. 
                      In this particular study, metabolic syndrome presence in HAART patients 
was reported less than documented for the general population. But the presence of type 2 
diabetes mellitus in this particular study was very high. Another important aspect in this 
study is the presence of two components of metabolic syndrome, majority of them did not 
met waist circumference to be included in the metabolic syndrome criteria. The high rate 
of body fat partitioning disturbances in this study also has to be noted [90]. 
e) Prevalence of hyperglycemia and dyslipidemia among HIV infected patients on 
HAART in Ethiopia: a cross - sectional comparative study 2014. 
                      In Burayu Health Centre, Ethiopia this study was conducted among HIV 
infected patients, which is a cross-sectional comparative study. Of 252 study participants, 
they were equally divided among HAART uninitiated and HAART initiated patients (126 
each). The prevalence of increased sugar levels, increased LDL - Cholesterol, elevated 
cholesterol levels, elevated triglyceride levels and decreased HDL  - Cholesterol were 
7.9%, 23%, 42.1%, 46.8% and 50.8% in HAART initiated patients and 5.6%, 7.1%, 
11.1%, 31% and 73% in HAART uninitiated patients.  There was statistically significant 
alteration in serum lipid profile levels in HAART patients and first-line HAART is 
associated with potentially atherogenic lipid profile levels [91].  
f) Dyslipidemia in AIDS patients on HAART- Brazil, Brazilian Journal of 
Infectious Diseases, April 2011. 
                 This cross-sectional study conducted in central Brazil documented the 
presence of abnormal lipid levels and other associated factors in HIV patients on 
HAART. A total of one hundred and thirteen patients were enumerated. Average age of 
the patients was 39.3 years; 68.1% were males; and 31.9% were females. The presence of 
lipid abnormalities was estimated to be 66.7%. Decreased HDL cholesterol level was the 
most common abnormality (53.5%), which is trailed by high Triglycerides (36.1%). 
Patients on HAART drugs with Protease inhibitor had a 5.2-fold increased possibility of 
dyslipidemia. The study stresses an increased prevalence rate of dyslipidemia on HAART 
[92].  
 
Indian studies 
 a) Metabolic syndrome in human immunodeficiency virus positive patients, 
Indian J of endocrinology and metabolism [94] 
                In this study, prevalence of metabolic syndrome was 20% among HIV-infected 
patients on HAART, which is the same as that of HIV negative patients. Majority had 
only one component of metabolic syndrome (32.85%). Low HDL cholesterol was present 
in 50% of patients followed by raised triglycerides in 42.85%. No patients had increased 
waist circumference. There was no statistically significant difference of risk factors and 
individual components of metabolic syndrome between those on HAART and those not 
on HAART. The limitations of the study being constraints of a time bound study and a 
small sample size. The results in this study are subject to type II error and thus cannot be 
generalized. 
b) Metabolic Syndrome and Sub Clinical Atherosclerosis: Influence of HIV Status 
and HAART, Sch. J. App. Med. Science [95] 
                     This one year study done in Jaipur was done among 100 HIV patients on 
HAART and 100 HIV patients who were not on HAART and 200 control subjects. 
Metabolic syndrome was diagnosed according to the guidelines from    the 2001 NCEP- 
ATP III. Sub clinical atherosclerosis was detected by carotid doppler studies. Metabolic 
syndrome was found in 15 (7.5%) control subjects (group A), 19 (19%) HIV cases who 
were not on HAART (group B) and 21 (21%) HIV cases on HAART (group C). They 
concluded as, compared with controls, HIV patients had a greater frequency of impaired 
fasting glucose, plasma triglycerides and HDL cholesterol and metabolic syndrome. 
Metabolic syndrome may be associated with increased chances of increased carotid 
intimal thickness and atherosclerosis. 
 
 
 
 
OBJECTIVES 
1) To study the prevalence of metabolic syndrome, dyslipidemia in HIV infected 
population. 
2) To study the individual components of metabolic syndrome as well as 
characteristics of lipid profiles among these patients. 
Place of study 
            ART clinic, stanley medical college and hospital. 
Study population 
             100 cases of seropositive HIV patients on HAART. 
Study period 
            March 2015 to July 2015. 
Study design 
           Prospective study. 
 
 
 
Case definition 
1) Seropositive HIV patients registered in ART clinic, on first line HAART 
(Lamivudine, Zidovudine, Nevirapine) for one year. 
2) Metabolic syndrome was defined as the presence of at least three of the following 
criteria: 
 The cut-off point of waist circumference is  ≥90 cm in males and ≥80 cm in 
females according to the recommendation by the World Health Organization 
(WHO) guidelines for South Asians 
 Triglycerides ≥150 mg/dL or medications for hypertriglyceridemia. 
 HDL-C < 40 mg/dL in males or <50 mg/dL in females or medications for low   
HDL-C.  
 Blood pressure ≥130/85 mmHg or medications for hypertension 
  Fasting blood glucose ≥100 mg/dL or medications for hyperglycemia 
 
3) Dyslipidemia is defined as TC ≥ 200 mg/dl, HDL-c < 40 mg/dl, LDL-c ≥ 130 
mg/dl, TG ≥ 150 mg/dl and TC/HDL-c ratio ≥ 5 by the United States National 
Cholesterol Education  Program, Adult Treatment Panel (NCEP-ATP) III 
guidelines.                     
 
   
 Inclusion criteria 
1) Age more than 18 years. 
2) Good ART adherence. (adherence of ≥ 95% for the past 6 months) 
3) Patients on first line HAART (Lamivudine, Zidovudine, Nevirapine) for one 
year. 
 
Exclusion criteria 
1) Receiving lipid altering therapy like statins and steroids. 
2) Pregnant women. 
3)  Renal failure. 
4) hypothyroidism 
 
Methodology 
              Patients aged above 18 years, who were HIV seropositive and taking HAART 
more than one year were included. For all participant members, information regarding 
socio demography information, body mass index, medical history (including diabetes 
mellitus, hypertension, renal failure, use of drugs that alter lipid profiles, and current use 
of anti-TB drugs) were compiled. CD4+ lymphocyte values were collected. The 
components of metabolic syndrome were defined according to the modified NCEP-ATP 
III criteria considering abdominal obesity as per World Health Organization (WHO) 
guidelines for South Asians. Waist circumference was measured using a non-elastic 
measuring tape at the highest level of iliac crest with the patient standing with feet 1 foot 
apart. Systolic and diastolic blood pressure was measured by sphygmomanometer. In all 
the patients, a peripheral venous blood sample was to be drawn in the morning after 8 - 
10 hours of fasting, to measure venous plasma glucose, serum total cholesterol, serum 
high density lipoprotein (HDL) cholesterol, and serum triglyceride levels. Serum glucose 
was to be measured by the glucose oxidase method; total cholesterol by cholestrol 
oxidase peroxidase method; HDL, LDL by PVS PEGME coupled precipitation method, 
triglycerides by glycerol phosphate oxidase method. The study period is from March – 
July 2015. 
HUMAN SUBJECT PROTECTION 
The full protocol along with draft questionnaire and Informed consent will be kept 
in Institutional ethical Committee and approval will be obtained.  
INFORMED CONSENT 
Consent form will be written in both English and Tamil and consent will be 
obtained from the participant, confidentiality will be maintained. 
 
 
 
EXPECTED BENEFITS FROM STUDY 
          The availability of HAART has tremendously increased for HIV positive patients. 
Being an important predictor of cardiovascular diseases dyslipidemia and metabolic 
syndrome has to be diagnosed and managed properly. The prevalence of dyslipidemia 
and metabolic syndrome in HIV patients on HAART in south Indian region will give an 
overview compared to other regions and countries. If the association is strong it 
emphasizes the need to screen for lipid profile before HAART initiation and also during 
the course of HAART.  
 
 
 
 
 
 
 
 
 
 
  
 DATA ANALYSIS 
                 The patients were divided into two groups by metabolic syndrome -ve and 
metabolic syndrome +ve groups.  Descriptive statistics was done for all data and were 
reported in terms of mean values and percentages. Suitable statistical tests of comparison 
were done. Continuous variables were analyzed with the unpaired t test. Categorical 
variables were analyzed with chi squared test and Fisher Exact Test. Statistical 
significance was taken as P < 0.05. The data was analyzed using SPSS version 16 and 
Microsoft Excel 2007.  
 Age  
 
 
 
Age 
Distribution 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
≤ 30 years 15 25.42 1 2.44 16 16.00 
31-40 years 31 52.54 9 21.95 40 40.00 
41-50 years 12 20.34 19 46.34 31 31.00 
51-60 years 1 1.69 12 29.27 13 13.00 
Total 59 100 41 100 100 100 
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Age Distribution Metabolic Syndrome -
ve 
Metabolic Syndrome +ve 
N 59 41 
Mean 34.93 46.12 
SD 6.99 6.94 
P value Unpaired t Test 0.0000 
Results  
          There is a true difference among study groups in relation to age distribution and 
this difference is considered to be statistically significant since p < 0.05 as per unpaired t 
test. In simple terms, Most of the metabolic syndrome -ve group patients belonged to the 
31-40 Years age class interval (n=31, 52.54%) with a mean age of 34.93 years. In the 
metabolic syndrome +ve group patients, majority belonged to the 41-50 Years age class 
interval (n=19, 46.34%) with a mean age of 46.12 years. This difference in age 
distribution among the study groups expressed a p-value of 0.0000.   
Discussion  
           The mean age was meaningfully less in metabolic syndrome -ve Group compared 
to metabolic syndrome +ve Group by 11.19 years. This significant difference of 1.32 
times increase in age in metabolic syndrome +ve Group compared to metabolic syndrome 
-ve Group is true and has not occurred by chance. 
Conclusion  
           In this study we can safely conclude that the incidence of metabolic syndrome 
among hiv – infected patients using HAART increased with age.   
  
 
Gender 
Distribution 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
Male 40 67.80 17 41.46 57 57.00 
Female 19 32.20 24 58.54 43 43.00 
Total 59 100 41 100 100 100 
P value Chi Squared Test 0.8438 
 
                    Majority of the metabolic syndrome -ve group patients belonged to the male 
gender group (n=40, 67.80%). In the metabolic syndrome +ve group patients, majority 
belonged to the female gender group (n=24, 58.54%). The association between the study 
groups and gender distribution is considered to be not statistically significant since p > 
0.05 as per chi squared test. 
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Duration 
of ART 
Metabolic 
Syndrome -
ve 
% Metabolic 
Syndrome 
+ve 
% All % 
3 years 26 44.07 1 2.44 27 27.00 
4 years 16 27.12 6 14.63 22 22.00 
5 years 16 27.12 22 53.66 38 38.00 
6 years 1 1.69 12 29.27 13 13.00 
Total 59 100 41 100 100 100 
 
 
Duration of ART Metabolic Syndrome -ve Metabolic Syndrome +ve 
N 59 41 
Mean 3.86 5.10 
SD 0.88 0.74 
P value Unpaired t Test 0.0000 
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Results  
             There is a true difference among study groups in relation to duration of ART and 
this difference is considered to be statistically significant since p < 0.05 as per unpaired t 
test. In simple terms, Most of the metabolic syndrome -ve group patients belonged to the 
3 years duration of ART class interval (n=26, 44.07%) with a mean duration of 3.86 
years. In the metabolic syndrome +ve group patients, majority belonged to the 5 Years 
duration of ART class interval (n=22, 53.66%) with a mean duration of 5.10 years. This 
difference in age distribution among the study groups expressed a p-value of 0.0000.   
Discussion  
               The mean duration of ART was meaningfully less in metabolic syndrome -ve 
Group compared to metabolic syndrome +ve Group by 1.23 years. This significant 
difference of 1.31 times increase in mean duration of ART in metabolic syndrome +ve 
Group compared to metabolic syndrome -ve Group is true and has not occurred by 
chance. 
Conclusion:  
                 In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART are significantly associated with longer duration 
of treatment.   
CD4 Count 
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CD4 Count Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
≤ 200 (cells/mm3) 1 1.69 4 9.76 5 5.00 
201-400 
(cells/mm3) 
12 20.34 15 36.59 27 27.00 
401-600 
(cells/mm3) 
20 33.90 9 21.95 29 29.00 
601-800 
(cells/mm3) 
8 13.56 7 17.07 15 15.00 
> 800 (cells/mm3) 18 30.51 6 14.63 0 0.00 
Total 59 100 41 100 76 76 
CD4 Count Metabolic Syndrome -ve Metabolic Syndrome +ve 
N 59 41 
Mean 653.37 501.10 
SD 292.50 269.93 
P value Unpaired t Test 0.0087 
Results  
            There is a true difference among study groups in relation to CD4 count and this 
difference is considered to be statistically significant since p < 0.05 as per unpaired t test. 
In simple terms, Most of the metabolic syndrome -ve group patients belonged to the 401-
600 (cells/mm3) CD4 count class interval (n=20, 33.90%) with a mean count of 653.37 
(cells/mm3). In the metabolic syndrome +ve group patients, majority belonged to the 
201-400 (cells/mm3) CD4 count class interval (n=15, 36.59%) with a mean count of 
501.10 (cells/mm3). This difference in CD4 count among the study groups expressed a p-
value of 0.0087.   
Discussion  
           The mean CD4 count was meaningfully more in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 152.28 (cells/mm3). This significant 
difference of 23% decrease in mean CD4 count in metabolic syndrome +ve group 
compared to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
 In this study we can safely conclude that metabolic syndrome patients among HIV – 
infected patients using HAART have significantly lower CD4 cell counts. 
     
 Systolic Blood Pressure 
 
 
 
Systolic Blood 
Pressure 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
≤ 100 mm Hg 14 23.73 2 4.88 16 16.00 
101-120 mm 
Hg 
32 54.24 14 34.15 46 46.00 
121-140 mm 
Hg 
11 18.64 16 39.02 27 27.00 
> 140 mm Hg 2 3.39 9 21.95 11 11.00 
Total 59 100 41 100 100 100 
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Systolic Blood Pressure Metabolic Syndrome -ve Metabolic Syndrome +ve 
N 59 41 
Mean 114.68 131.22 
SD 13.89 16.70 
P value Unpaired t Test 0.0000 
Results  
            There is a true difference among study groups in relation to systolic blood 
pressure and this difference is considered to be statistically significant since p < 0.05 as 
per unpaired t test. In simple terms, Most of the metabolic syndrome -ve group patients 
belonged to the 101-120 mm Hg class interval (n=32, 54.24%) with a mean SBP of 
114.68 mm Hg.  In the metabolic syndrome +ve group patients, majority belonged to the 
121-140 mm Hg class interval (n=16, 39.02%) with a mean SBP of 131.22 mm Hg. This 
difference in SBP among the study groups expressed a p-value of 0.0000.   
Discussion  
               The mean systolic blood pressure was meaningfully less in metabolic syndrome 
-ve Group compared to metabolic syndrome +ve group by 16.54 mm Hg. This significant 
difference of 1.14 times increase in mean SBP in metabolic syndrome +ve Group 
compared to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
             In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher systolic blood pressure 
levels.  
 
 
 
Diastolic Blood Pressure 
 
 
 
Diastolic 
Blood 
Pressure 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
≤ 80 mm Hg 43 72.88 18 43.90 61 61.00 
81-90 mm 
Hg 
14 23.73 16 39.02 30 30.00 
91-100 mm 
Hg 
2 3.39 7 17.07 9 9.00 
Total 59 100 41 100 100 100 
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Diastolic Blood 
Pressure 
Metabolic Syndrome -ve Metabolic Syndrome +ve 
N 59 41 
Mean 78.54 84.39 
SD 7.04 8.13 
P value Unpaired t Test 0.0004 
Results  
             There is a true difference among study groups in relation to diastolic blood 
pressure and this difference is considered to be statistically significant since p < 0.05 as 
per unpaired t test. In simple terms, Most of the metabolic syndrome -ve group patients 
belonged to the ≤ 80 mm Hg class interval (n=45, 72.88%) with a mean DBP of 78.54 
mm Hg. In the metabolic syndrome +ve group patients, majority belonged to the ≤ 80 
mm Hg class interval (n=18, 43.90%) with a mean DBP of 84.39 mm Hg. This difference 
in DBP among the study groups expressed a p-value of 0.0004.   
Discussion  
            The mean diastolic blood pressure was meaningfully less in metabolic syndrome -
ve group compared to metabolic syndrome +ve group by 5.85 mm Hg. This significant 
difference of 1.07 times increase in mean DBP in metabolic syndrome +ve group 
compared to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
             In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher DBP levels.  
Hypertension 
 
 
 
Hypertension 
Status 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
Hypertensive 8 13.56 22 53.66 30 30.00 
Non 
Hypertensive 
51 86.44 19 46.34 70 70.00 
Total 59 100 41 100 100 100 
P value Chi Squared Test 0.0001 
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Result  
              There is a true difference among study groups study groups in relation to 
hypertension status and this difference is considered to be statistically significant since p 
< 0.05 as per chi squared test. Most of the metabolic syndrome -ve group patients are non 
hypertensive (n=51, 86.44%). In the metabolic syndrome +ve group patients, majority 
were hypertensive (n=22, 53.66%). This hypertension status distribution among the study 
groups expressed a p-value of 0.0001.   
Discussion  
                The incidence of hypertension was meaningfully less in metabolic syndrome -
ve group compared to metabolic syndrome +ve group by 40.10 percentage points. This 
significant difference of 3.96 times increase in incidence of hypertension in metabolic 
syndrome +ve group compared to metabolic syndrome -ve group is true and has not 
occurred by chance.  
Conclusion  
              In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher incidence of 
hypertension.  
  
FBS 
 
 
 
Fasting 
Blood Sugar 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
≤ 80 mg/dl 14 23.73 5 12.20 19 19.00 
81-100 
mg/dl 
42 71.19 22 53.66 64 64.00 
101-120 
mg/dl 
3 5.08 14 34.15 0 0.00 
Total 59 100 41 100 83 83 
 
 
Fasting Blood Sugar Metabolic Syndrome -ve Metabolic Syndrome +ve 
N 59 41 
Mean 85.93 94.95 
SD 8.38 12.31 
P value Unpaired t Test 0.0001 
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 Results  
              There is a true difference among study groups in relation to fasting blood sugar 
levels and this difference is considered to be statistically significant since p < 0.05 as per 
unpaired t test. Most of the metabolic syndrome -ve group patients belonged to 81-100 
mg/dl FBS class interval (n=42, 71.19%) with a mean FBS of 85.93mg/dl.  In the 
metabolic syndrome +ve group patients, majority belonged to 81-100 mg/dl FBS class 
interval (n=22, 53.66%) with a mean FBS of 94.95/dl.  This difference in FBS among the 
study groups expressed a p-value of 0.0001.   
Discussion  
               The mean fasting blood sugar was meaningfully less in metabolic syndrome -ve 
group compared to metabolic syndrome +ve group by 9.02 mg/dl. This significant 
difference of 1.10 times increase in mean FBS in metabolic syndrome +ve group 
compared to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
                 In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher fasting blood sugar 
levels.  
 
 
 Diabetes Mellitus 
 
 
 
Diabetes 
Mellitus 
Status 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
Diabetic 3 5.08 21 51.22 24 24.00 
Non 
Diabetic 
56 94.92 20 48.78 76 76.00 
Total 59 100 41 100 100 100 
P value Fishers Exact Test 0.0001 
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Result  
            There is a true difference among study groups in relation to diabetes status and 
this difference is considered to be statistically significant since p < 0.05 as per fishers 
exact test. Most of the metabolic syndrome -ve group patients are non diabetics (n=56, 
94.92%). In the metabolic syndrome +ve group patients, majority were diabetics (n=20, 
48.78%). This diabetes status distribution among the study groups expressed a p-value of 
0.0001.   
Discussion  
              The incidence of diabetes was meaningfully less in metabolic syndrome -ve 
group compared to metabolic syndrome +ve group by 46.13 percentage points. This 
significant difference of 10.07 times increase in incidence of diabetes in metabolic 
syndrome +ve group compared to metabolic syndrome -ve group is true and has not 
occurred by chance.  
Conclusion  
              In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher incidence of diabetes.  
  
Abdominal Circumference 
 
 
 
Abdominal 
Circumference 
Status 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
≤ 80 cms 26 44.07 4 9.76 30 30.00 
81-90 cms 31 52.54 22 53.66 53 53.00 
91-100 cms 2 3.39 15 36.59 17 17.00 
Total 59 100 41 100 100 100 
 
 
Abdominal Circumference 
Status 
Metabolic Syndrome -
ve 
Metabolic Syndrome +ve 
N 59 41 
Mean 79.96 87.76 
SD 5.50 5.51 
P value Unpaired t Test 0.0000 
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Results  
              There is a true difference among study groups in relation to abdominal 
circumference measurements and this difference is considered to be statistically 
significant since p < 0.05 as per unpaired t test. Most of the metabolic syndrome -ve 
group patients belonged to 81-90 cm abdominal circumference class interval (n=31, 
52.54%) with a mean AC of 79.76 cm. In the metabolic syndrome +ve group patients, 
majority belonged 81-90 cm abdominal circumference class interval (n=22, 53.66%) with 
a mean AC of 87.76 cm. This difference in AC among the study groups expressed a p-
value of 0.0001.   
Discussion 
               The mean abdominal circumference was meaningfully less in metabolic 
syndrome -ve group compared to metabolic syndrome +ve group by 7.80 cm. This 
significant difference of 1.10 times increase in mean AC  in metabolic syndrome +ve 
group compared to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
                In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher abdominal 
circumference measurements.  
Abdominal Circumference Status 
 
 
Abdominal 
Circumference 
Status 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
Abnormal AC 5 8.47 34 82.93 39 39.00 
Normal AC 54 91.53 7 17.07 61 61.00 
Total 59 100 41 100 100 100 
P value Fishers Exact Test 0.0001 
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Result  
              There is a true difference among study groups study groups in relation to 
Abdominal Circumference status and this difference is considered to be statistically 
significant since p < 0.05 as per fishers exact test. Most of the metabolic syndrome -ve 
group patients have normal AC (n=54, 91.53%). In the metabolic syndrome +ve group 
patients, majority have abnormal AC (n=34, 82.93%). This Abdominal Circumference 
status distribution among the study groups expressed a p-value of 0.0001.   
Discussion  
             The incidence of abnormal AC was meaningfully less in metabolic syndrome -ve 
Group compared to metabolic syndrome +ve Group by 74.45 percentage points. This 
significant difference of 9.79 times increase in incidence of abnormal AC in metabolic 
syndrome +ve Group compared to metabolic syndrome -ve Group is true and has not 
occurred by chance.  
Conclusion  
            In this study we can safely conclude that metabolic syndrome patients among HIV 
– infected patients using HAART have significantly higher abdominal circumferences.  
High Density Lipoprotein 
 
 
 
High 
Density 
Lipoprotein 
Status 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
31-40 mg/dl 18 30.51 19 46.34 37 37.00 
41-50 mg/dl 32 54.24 18 43.90 50 50.00 
51-60 mg/dl 9 15.25 4 9.76 13 13.00 
Total 59 100 41 100 100 100 
 
High Density Lipoprotein 
Status 
Metabolic Syndrome -
ve 
Metabolic Syndrome +ve 
N 59 41 
Mean 43.80 40.63 
SD 5.70 5.62 
P value Unpaired t Test 0.0072 
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Results  
               There is a true difference among study groups in relation to high density 
lipoprotein measurements and this difference is considered to be statistically significant 
since p < 0.05 as per unpaired t test. Most of the metabolic syndrome -ve group patients 
belonged to 41-50 mg/dl HDL class interval (n=32, 54.24%) with a mean HDL level of 
43.80 mg/dl.  In the metabolic syndrome +ve group patients, majority belonged 31-40 
mg/dl HDL class interval (n=19, 46.34%) with a mean HDL level of 40.63 mg/dl. This 
difference in HDL levels among the study groups expressed a p-value of 0.0072.   
Discussion  
                The mean HDL level was meaningfully more in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 3.16 mg/dl. This significant difference of 
7% decrease in mean HDL levels in metabolic syndrome +ve Group compared to 
metabolic syndrome -ve Group is true and has not occurred by chance. 
Conclusion  
               In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly lower HDL levels.  
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High 
Density 
Lipoprotein 
Status 
Metabolic 
Syndrome 
-ve 
% Metabolic 
Syndrome 
+ve 
% All % 
Abnormal 
HDL 
28 47.46 37 90.24 65 65.00 
Normal 
HDL 
31 52.54 4 9.76 35 35.00 
Total 59 100 41 100 100 100 
P value Fishers Exact Test 0.0001 
Result  
                  There is a true difference among study groups in relation to high density 
lipoprotein status and this difference is considered to be statistically significant since p < 
0.05 as per fishers exact test. Most of the metabolic syndrome -ve group patients have 
normal HDL levels (n=31, 52.54%). In the metabolic syndrome +ve group patients, 
majority have abnormal HDL levels (n=37, 90.24%). This high density lipoprotein status 
distribution among the study groups expressed a p-value of 0.0001.   
Discussion  
                  The incidence of abnormal HDL levels was meaningfully less in metabolic 
syndrome -ve group compared to metabolic syndrome +ve group by 42.79 percentage 
points. This significant difference of 1.90 times increase in incidence of abnormal HDL 
levels in metabolic syndrome +ve group compared to metabolic syndrome -ve group is 
true and has not occurred by chance.  
Conclusion  
                  In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher abnormal HDL levels.  
  
Triglycerides 
 
 
 
Triglycerides 
Status 
MetS -ve % MetS +ve % All % 
≤ 130 mg/dl 16 27.12 1 2.44 17 17.00 
131-150 
mg/dl 
37 62.71 7 17.07 44 44.00 
151-170 
mg/dl 
3 5.08 21 51.22 24 24.00 
> 170 mg/dl 3 5.08 12 29.27 15 15.00 
Total 59 100 41 100 100 100 
 
Triglycerides Status MetS -ve MetS +ve 
N 59 41 
Mean 136.85 167.93 
SD 17.88 24.97 
P value Unpaired t Test 0.0000 
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Results  
               There is a true difference among study groups in relation to triglyceride 
measurements and this difference is considered to be statistically significant since p < 
0.05 as per unpaired t test. Most of the metabolic syndrome -ve group patients belonged 
to 131-150 mg/dl TGL class interval (n=37, 62.71%) with a mean TGL level of 136.85 
mg/dl.  In the metabolic syndrome +ve group patients, majority belonged 151-170 mg/dl 
TGL class interval (n=21, 51.22%) with a mean TGL level of 167.93 mg/dl. This 
difference in TGL levels among the study groups expressed a p-value of 0.0000.   
Discussion  
                 The mean TGL level was meaningfully more in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 31.08 mg/dl. This significant difference 
of 1.23 times increase  in mean TGL levels  in metabolic syndrome +ve group compared 
to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
                 In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher TGL levels.  
  
Triglycerides 
Status 
MetS -ve % MetS 
+ve 
% All % 
Abnormal 
TGL 
6 10.17 33 80.49 39 39.00 
Normal TGL 53 89.83 8 19.51 61 61.00 
Total 59 100 41 100 100 100 
P value Chi Squared Test 0.0001 
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 Result  
              There is a true difference among study groups in relation to triglycerides status 
and this difference is considered to be statistically significant since p < 0.05 as per chi 
squared test. Most of the metabolic syndrome -ve group patients have normal TGL levels 
(n=53, 89.83%). In the metabolic syndrome +ve group patients, majority have abnormal 
TGL levels (n=33, 80.49%). This triglycerides status distribution among the study groups 
expressed a p-value of 0.0001.   
Discussion  
               The incidence of abnormal TGL levels was meaningfully less in metabolic 
syndrome -ve group compared to metabolic syndrome +ve group by 70.32 percentage 
points. This significant difference of 7.91 times increase in incidence of abnormal TGL 
levels in metabolic syndrome +ve group compared to metabolic syndrome -ve group is 
true and has not occurred by chance.  
Conclusion  
                 In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher abnormal TGL levels.  
  
Total Cholesterol 
 
 
 
Total 
Cholesterol 
Status 
MetS -ve % MetS +ve % All % 
≤ 200 mg/dl 54 91.53 16 39.02 70 70.00 
201-250 
mg/dl 
5 8.47 23 56.10 28 28.00 
> 250 mg/dl 0 0.00 2 4.88 2 2.00 
Total 59 100 41 100 100 100 
 
 
Total Cholesterol Status MetS -ve MetS +ve 
N 59 41 
Mean 185.80 211.73 
SD 11.50 21.82 
P value Unpaired t Test 0.0000 
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 Results  
              There is a true difference among study groups in relation to total cholesterol 
levels and this difference is considered to be statistically significant since p < 0.05 as per 
unpaired t test. Most of the metabolic syndrome -ve group patients belonged to ≤ 200 
mg/dl TC class interval (n=54, 91.53%) with a mean TC level of 185.80 mg/dl.  In the 
metabolic syndrome +ve group patients, majority belonged 201-250 mg/dl TC class 
interval (n=23, 56.10%) with a mean TC level of 211.73 mg/dl. This difference in TC 
levels among the study groups expressed a p-value of 0.0000.   
Discussion  
               The mean TC level was meaningfully less in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 25.94 mg/dl. This significant difference 
of 1.14 times increase  in mean TC levels  in metabolic syndrome +ve group compared to 
metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
               In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher TC levels.  
  
Total 
Cholesterol 
Status 
MetS -ve % MetS 
+ve 
% All % 
Abnormal 
TC 
5 8.47 25 60.98 30 30.00 
Normal TC 54 91.53 16 39.02 70 70.00 
Total 59 100 41 100 100 100 
P value Fishers Exact Test 0.0001 
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Result  
                  There is a true difference among study groups in relation to total cholesterol 
status and this difference is considered to be statistically significant since p < 0.05 as per 
fishers exact test. Most of the metabolic syndrome -ve group patients have normal TC 
levels (n=54, 91.53%). In the metabolic syndrome +ve group patients, majority have 
abnormal TC levels (n=25, 60.98%). This TC status distribution among the study groups 
expressed a p-value of 0.0001.   
Discussion  
                   The incidence of abnormal TC levels was meaningfully less in metabolic 
syndrome -ve group compared to metabolic syndrome +ve group by 52.50 percentage 
points. This significant difference of 7.20 times increase in incidence of abnormal TC 
levels in metabolic syndrome +ve group compared to metabolic syndrome -ve group is 
true and has not occurred by chance.  
Conclusion  
                   In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher abnormal TC levels.  
  
Low Density Lipoprotein 
 
 
 
Low Density 
Lipoprotein 
Status 
MetS -ve % MetS +ve % All % 
≤ 120 mg/dl 33 55.93 10 24.39 43 43.00 
121-140 
mg/dl 
26 44.07 17 41.46 43 43.00 
141-160 
mg/dl 
0 0.00 14 34.15 14 14.00 
Total 59 100 41 100 100 100 
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Low Density Lipoprotein 
Status 
MetS -ve MetS +ve 
N 59 41 
Mean 118.37 131.46 
SD 7.94 13.65 
P value Unpaired t Test 0.0000 
Results  
                  There is a true difference among study groups in relation to low density 
lipoprotein levels and this difference is considered to be statistically significant since p < 
0.05 as per unpaired t test. Most of the metabolic syndrome -ve group patients belonged 
to ≤ 120 mg/dl LDL class interval (n=33, 55.93%) with a mean LDL level of 118.37 
mg/dl.  In the metabolic syndrome +ve group patients, majority belonged 121-140 mg/dl 
LDL class interval (n=17, 41.46%) with a mean LDL level of 131.46 mg/dl.   This 
difference in LDL levels among the study groups expressed a p-value of 0.0000.   
Discussion  
                     The mean LDL level was meaningfully less in metabolic syndrome -ve 
Group compared to metabolic syndrome +ve group by 13.09 mg/dl. This significant 
difference of 1.11 times increase in mean LDL levels in metabolic syndrome +ve Group 
compared to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
                    In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher LDL levels.  
  
Low Density 
Lipoprotein 
Status 
MetS -ve % MetS +ve % All % 
Abnormal 
LDL 
3 5.08 22 53.66 25 25.00 
Normal LDL 56 94.92 19 46.34 75 75.00 
Total 59 100 41 100 100 100 
P value Fishers Exact Test 0.0001 
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 Result  
               There is a true difference among study groups in relation to low density 
lipoproteins status and this difference is considered to be statistically significant since p < 
0.05 as per fishers exact test. Most of the metabolic syndrome -ve group patients have 
normal LDL levels (n=56, 94.92%). In the metabolic syndrome +ve group patients, 
majority have abnormal LDL levels (n=22, 53.66%). This LDL status distribution among 
the study groups expressed a p-value of 0.0001.   
Discussion  
               The incidence of abnormal TC levels was meaningfully less in metabolic 
syndrome -ve group compared to metabolic syndrome +ve group by 48.57 percentage 
points. This significant difference of 10.55 times increase in incidence of abnormal LDL 
levels in metabolic syndrome +ve group compared to metabolic syndrome -ve group is 
true and has not occurred by chance.  
Conclusion  
             In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher abnormal LDL levels.  
  
TC/LDL Ratio 
 
 
 
TC/LDL 
Ratio 
MetS -ve % MetS +ve % All % 
≤ 4 29 49.15 3 7.32 32 32.00 
4.1-5 22 37.29 18 43.90 40 40.00 
5.1-6 7 11.86 11 26.83 18 18.00 
> 6 1 1.69 9 21.95 10 10.00 
Total 59 100 41 100 100 100 
 
 
TC/LDL Ratio MetS -ve MetS +ve 
N 59 41 
Mean 4.24 5.27 
SD 0.69 0.91 
P value Unpaired t Test 0.0000 
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Results  
              There is a true difference among study groups in relation to low density 
lipoprotein levels and this difference is considered to be statistically significant since p < 
0.05 as per unpaired t test. Most of the metabolic syndrome -ve group patients belonged 
to ≤ 4 TC/LDL ratio class interval (n=29, 49.15%) with a mean TC/LDL ratio of 4.24.  In 
the metabolic syndrome +ve group patients, majority belonged 4.1-5 TC/LDL ratio class 
interval (n=18, 43.90%) with a mean TC/LDL ratio of 5.27.   This difference in TC/LDL 
ratio among the study groups expressed a p-value of 0.0000.   
Discussion  
              The mean TC/LDL ratio was meaningfully less in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 1.03 points. This significant difference of 
1.24 times increase  in mean TC/LDL ratio in metabolic syndrome +ve group compared 
to metabolic syndrome -ve group is true and has not occurred by chance. 
Conclusion  
               In this study we can safely conclude that metabolic syndrome patients among 
HIV – infected patients using HAART have significantly higher TC/LDL ratio levels.  
  
TC/LDL Ratio MetS -
ve 
% MetS 
+ve 
% All % 
Abnormal TC/LDL 
Ratio 
10 16.95 25 60.98 35 35.00 
Normal TC/LDL 
Ratio 
49 83.05 16 39.02 65 65.00 
Total 59 100 41 100 100 100 
P value Chi Squared Test 0.0001 
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Result  
            There is a true difference among study groups in relation to TC/LDL ratio status 
and this difference is considered to be statistically significant since p < 0.05 as per fishers 
exact test. Most of the metabolic syndrome -ve group patients have normal TC/LDL ratio 
(n=56\\49, 63.05%). In the metabolic syndrome +ve group patients, majority have 
abnormal TC/LDL ratio (n=25, 60.98%). This TC/LDL ratio distribution among the 
study groups expressed a p-value of 0.0001.   
Discussion  
           The incidence of abnormal TC/LDL ratio levels was meaningfully less in 
metabolic syndrome -ve group compared to metabolic syndrome +ve group by 44.03 
percentage points. This significant difference of 3.60 times increase in incidence of 
abnormal TC/LDL ratio levels in metabolic syndrome +ve group compared to metabolic 
syndrome -ve group is true and has not occurred by chance.  
Conclusion  
          In this study we can safely conclude that metabolic syndrome patients among HIV 
– infected patients using HAART have significantly higher abnormal TC/LDL ratio 
levels.  
  
Metabolic syndrome (out of 5) 
 
 
Metabolic 
syndrome 
(out of 5) 
MetS -ve % MetS 
+ve 
% All % 
0 of 5 25 42.37 0 0.00 25 25.00 
1 of 5 18 30.51 0 0.00 18 18.00 
2 of 5 16 27.12 0 0.00 16 16.00 
3 of 5 0 0.00 23 56.10 23 23.00 
4 of 5 0 0.00 12 29.27 12 12.00 
5 of 5 0 0.00 6 14.63 6 6.00 
Total 59 100 41 100 100 100 
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CONCLUSIONS 
The following were the conclusion of this study  
 The association between the study groups and age distribution is considered to be 
statistically significant. Most of the metabolic syndrome -ve group patients had a 
mean age of 34.93 years. In the metabolic syndrome +ve Group patients, had a 
mean age of 46.12 years. 
  
 The association between the study groups and gender distribution is considered to 
be not statistically significant.  
 
 We can conclude that metabolic syndrome among HIV – infected patients using 
HAART are significantly associated with longer duration of treatment.   
 
 The metabolic syndrome positive group among HIV – infected patients using 
HAART have significantly lower CD4 cell counts which was statistically 
significant.  
 
 Association between the metabolic syndrome positive group and hypertension, 
diabetes mellitus, abdominal circumference, triglyceride levels, altered HDL levels 
were considered to be statistically significant. 
  The mean TC levels was meaningfully less in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 25.94 mg/dl, which infers that 
metabolic syndrome patients among HIV – infected patients using HAART have 
significantly higher TC levels.  
 
 The mean LDL levels was meaningfully less in metabolic syndrome -ve group 
compared to metabolic syndrome +ve group by 13.09 mg/dl and the difference is 
significant. 
 
 We can safely conclude that metabolic syndrome patients among HIV – infected 
patients using HAART have significantly higher TC/LDL ratio levels.  
 
 The prevalence of metabolic syndrome in our study is 41%. Patients with no 
components of metabolic syndrome (0/5) was 25%, one component was (1/5) 
18%, two components of metabolic syndrome (2/5) was 16% and 3/5, 4/5, 5/5 
being 23%, 12%, 06% respectively. As I had already quoted, a range of studies 
across the globe has given a wide prevalence for metabolic syndrome in the HIV 
population which ranges from 11.2% up to 45.4%. 
  
 Also we have to keep in mind that the HIV patients on HAART, included in our 
study were on drugs for more than 3 years, which might explain the high 
prevalence. The prevalence of metabolic syndrome in Indian population also varies, 
and a recent study done in Maharashtra puts the prevalence around 19.52% [96]. 
  
 The prevalence of dyslipidemia in our study was 71%, with abnormal HDL, high 
triglycerides, high total cholesterol, high LDL and high TC/LDL ratio being 65%, 
39%, 30%, 25%, 35% respectively. 
   
 The prevalence of dyslipidemia in HAART patients in a Brazilian study [92] was 
66.7% with low HDL was the most frequent abnormality (53.5%), followed by 
high TG (36.1%). To look for the prevalence of dyslipidemia in Indian population, 
a fine study – ICMR INDIAB [97] which quotes abnormal HDL, high triglycerides, 
high total cholesterol and high LDL being 72.3%, 29.5%, 13.9%, 11.8% 
respectively with a prevalence of 79%. 
  
 We conclude that HIV patients on HAART have high prevalence of metabolic 
syndrome and lipid abnormalities, and they should be regularly screened for the 
same and appropriately managed. 
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நாᾹ எᾸதெவாᾞ ேவைளயிᾤΆ ஆᾼவி᾿ இᾞᾸᾐ திᾞΆப ᾙᾊᾜΆ, அதᾹ பிᾹன᾽, 
நாᾹ வழᾰகΆ ேபா᾿ மᾞᾷᾐவசிகிᾲைச ெபறᾙᾊᾜΆ எᾹᾠ ᾗாிᾸᾐ ெகா῀கிேறᾹ. 
நாᾹ ஆᾼவி᾿ பᾱᾁ எᾌᾷᾐ பணΆ எைதᾜΆ ெபற ᾙᾊயாᾐ எᾹᾠ 
அறிᾸᾐ῀ேளᾹ.  இᾸத ஆᾼவிᾹ ᾙᾊᾫக῀ எᾸத ெமᾊᾰக᾿ ஜ᾽னᾢ᾿ ெவளியிடᾺபட 
இᾞᾸதா᾿ நாᾹ எதி᾽ᾰகவி᾿ைல, எᾹ தனிᾺப᾵ட அைடயாளᾷைத ெவளிᾺபᾌᾷதᾺப᾵ᾌ 
இᾞᾰக ᾂடாᾐ. 
நாᾹ இᾸத ஆᾼவி᾿ பᾱெகᾌᾺபதᾹ ᾚலΆ நாᾹ எᾹன ெசᾼய ேபாகிேறᾹ எᾹᾠ 
ெதாிᾜΆ. நாᾹ இᾸத ஆᾼவி᾿ எᾹ ᾙᾨ ஒᾷᾐைழᾺைபᾜΆ ெகாᾌᾺேபᾹ எᾹᾠ 
உᾠதியளிᾰகிேறᾹ. 
தᾹனா᾽வள᾽       சா᾵சி  
ெபய᾽ மιᾠΆ ᾙகவாி     ெபய᾽ மιᾠΆ ᾙகவாி 
ைகெயாᾺபΆ  / விர᾿ேரைக:     ைகெயாᾺபΆ / விர᾿ேரைக: 
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1 35 F 4 588 140/90 Y 90 N 78 N 34 Y 130 N 180 N 122 N 5.2 Y 2 
2 30 M 3 554 120/80 N 86 N 85 N 38 Y 126 N 176 N 110 N 4.6 N 1 
3 25 F 3 761 126/80 N 82 N 75 N 52 N 110 N 196 N 106 N 3.7 N 0 
4 47 F 5 493 140/94 Y 110 Y 86 Y 56 N 166 Y 210 Y 134 Y 3.7 N 4 
5 28 M 3 839 110/70 N 82 N 82 N 44 N 104 N 182 N 106 N 4.1 N 0 
6 30 F 3 529 150/100 Y 70 N 70 N 45 Y 134 N 206 Y 110 N 4.5 N 2 
7 50 M 5 1124 110/70 N 72 N 94 Y 37 Y 270 Y 196 N 126 N 5.2 Y 3 
8 45 F 6 1004 100/70 N 91/KDM Y 92 Y 42 Y 220 Y 210 Y 102 N 5 Y 4 
9 36 M 5 1087 160/90 Y 86 N 96 Y 34 Y 142 N 240 Y 114 N 7 Y 3 
10 32 F 4 368 106/72 N 91 N 70 N 52 N 104 N 166 N 104 N 3.1 N 0 
11 35 M 3 441 126/82 N 116 Y 79 N 44 N 110 N 174 N 113 N 3.5 N 1 
12 40 M 3 374 110/82 N 85 N 85 N 32 Y 144 N 198 N 120 N 6.1 Y 1 
13 48 F 6 272 140/96 Y 88 N 84 Y 38 Y 135 N 184 N 130 Y 4.8 N 3 
14 34 F 3 304 90/70 N 75 N 75 N 51 N 106 N 172 N 112 N 3.1 N 0 
15 50 M 6 592 134/90 Y 98/KDM Y 92 Y 36 Y 170 Y 206 Y 114 N 5.7 Y 5 
16 33 M 4 378 116/70 N 88 N 83 N 38 Y 180 Y 224 Y 112 N 5.8 Y 2 
17 32 M 3 776 106/70 N 78 N 70.5 N 44 N 146 N 182 N 125 N 3.3 N 0 
18 25 F 3 1041 100/74 N 92 N 74 N 46 Y 136 N 176 N 104 N 3.8 N 1 
19 27 F 4 344 150/90 Y 85 N 79 N 44 Y 190 Y 210 Y 116 N 4.7 N 3 
20 42 M 3 366 126/80 N 108 Y 84 Y 48 N 128 N 190 N 124 N 3.9 N 2 
21 52 F 5 529 114/70 N 76 N 92 Y 34 Y 186 Y 188 N 110 N 5.5 Y 3 
22 32 F 3 597 100/76 N 84 N 85 N 38 Y 142 N 174 N 134 Y 4.5 N 1 
23 30 M 3 886 120/80 N 72 N 72 N 48 N 135 N 192 N 116 N 4 N 0 
24 54 F 5 468 
160/100
/KHT Y 88 N 75 N 42 Y 174 Y 210 Y 124 N 5 Y 3 
25 47 F 6 208 124/80 N 
114/KD
M Y 84 Y 40 Y 166 Y 244 Y 146 Y 6.1 Y 4 
26 38 M 5 605 120/84 N 106 Y 95 Y 35 Y 144 N 184 N 121 N 5.2 Y 3 
27 36 F 3 1137 106/80 N 75 N 76 N 42 Y 148 N 198 N 126 N 4.7 N 1 
28 48 M 3 625 140/86 Y 94 N 82 N 48 N 162 Y 204 Y 132 Y 4.2 N 2 
29 45 F 5 974 
140/100
/KHT Y 98/KDM Y 75 N 44 Y 130 N 196 N 118 N 4.4 N 3 
30 29 M 3 459 120/76 N 89 N 85 N 46 N 147 N 186 N 120 N 4 N 0 
31 23 M 3 1648 100/74 N 94 N 78 N 46 N 128 N 194 N 126 N 4.2 N 0 
32 32 F 4 569 110/80 N 88 N 71 N 51 N 136 N 182 N 110 N 3.5 N 0 
33 40 F 5 898 150/90 Y 108 Y 86 Y 42 Y 169 Y 264 Y 152 Y 6.2 Y 5 
34 48 M 5 1040 120/78 N 92 N 93 Y 45 N 176 Y 178 N 122 N 3.9 N 2 
35 37 M 6 445 126/80 N 114 Y 95 Y 36 Y 166 Y 216 Y 160 Y 6 Y 4 
36 27 F 3 464 110/82 N 85 N 75 N 45 Y 139 N 183 N 124 N 4 N 1 
37 30 M 4 1146 106/80 N 91 N 85 N 44 N 144 N 189 N 120 N 4.2 N 0 
38 43 F 4 268 116/76 N 96 N 88 Y 42 Y 172 Y 196 N 116 N 4.6 N 3 
39 52 F 6 205 140/96 Y 90 N 85 Y 41 Y 168 Y 228 Y 146 Y 5.5 Y 4 
40 34 M 3 449 100/80 N 82 N 73 N 54 N 140 N 188 N 122 N 3.4 N 0 
41 28 M 4 935 114/80 N 88 N 76 N 48 N 114 N 175 N 118 N 3.6 N 0 
42 31 F 3 865 126/80 N 79 N 74 N 46 Y 131 N 190 N 127 N 4.1 N 1 
43 45 F 5 682 146/90 Y 72 N 83 Y 43 Y 142 N 194 N 118 N 4.5 N 3 
44 47 M 5 392 110/80 N 104 Y 86 N 35 Y 186 Y 210 Y 124 N 6 Y 3 
45 52 F 5 534 120/84 N 93/KDM Y 88 Y 41 Y 162 Y 193 N 138 Y 4.7 N 4 
46 33 M 4 553 100/76 N 89 N 74 N 52 N 144 N 187 N 116 N 3.5 N 0 
47 30 F 3 808 110/82 N 95 N 77 N 46 Y 138 N 182 N 122 N 3.9 N 1 
48 52 F 6 727 160/90 Y 98/KDM Y 85 Y 42 Y 166 Y 214 Y 147 Y 5 Y 5 
49 48 M 4 372 
140/80/
KHT Y 82 N 86 N 36 Y 135 N 171 N 124 N 4.7 N 2 
50 53 F 5 102 100/70 N 78 N 88 Y 44 Y 162 Y 208 Y 135 Y 4.7 N 3 
51 50 M 6 592 110/80 N 88 N 74 N 35 Y 134 N 189 N 114 N 4.2 N 1 
52 32 M 3 863 100/76 N 85 N 82 N 44 N 137 N 191 N 123 N 4.8 N 0 
53 39 M 4 153 150/80 Y 93 N 86 N 37 Y 128 N 182 N 127 N 4.9 N 2 
54 50 F 4 340 110/76 N 108 Y 85 Y 43 Y 142 N 188 N 125 N 4.3 N 3 
55 32 M 5 792 100/76 N 91 N 81 N 45 N 144 N 178 N 118 N 3.9 N 0 
56 41 F 6 379 120/78 N 114 Y 88 Y 42 Y 172 Y 245 Y 146 Y 5.8 Y 4 
57 55 F 5 483 150/96 Y 84 N 84 Y 52 N 168 Y 191 N 134 Y 3.8 N 3 
58 33 M 4 543 110/84 N 79 N 83 N 35 Y 135 N 173 N 116 N 4.9 N 1 
59 43 F 4 624 120/76 N 82 N 75 N 45 Y 165 Y 224 Y 122 N 4.9 N 2 
60 35 M 5 469 140/92 Y 81 N 89 Y 53 N 162 Y 210 Y 141 Y 3.9 N 3 
61 50 M 4 226 146/90 Y 
95/ 
KDM Y 95 Y 36 Y 155 Y 214 Y 142 Y 5.9 Y 5 
62 31 M 4 806 100/70 N 79 N 84 N 45 N 144 N 192 N 124 N 4.2 N 0 
63 36 F 4 317 140/100 Y 82 N 76 N 44 Y 163 Y 193 N 115 N 4.3 N 3 
64 34 M 5 862 110/86 N 91 N 83 Y 38 Y 132 N 188 N 108 N 4.9 N 2 
65 42 F 4 450 100/74 N 85 N 75 N 45 Y 113 N 194 N 120 N 4.3 N 1 
66 24 M 3 837 120/76 N 76 N 82 N 48 N 148 N 174 N 110 N 3.6 N 0 
67 47 F 6 373 130/90 Y 108 Y 86 Y 52 N 159 Y 228 Y 144 Y 4.3 N 4 
68 33 M 3 384 110/74 N 85 N 93 Y 36 Y 162 Y 182 N 126 N 5 Y 3 
69 33 M 5 364 100/70 N 92 N 85 N 37 Y 139 N 206 Y 128 N 5.5 Y 1 
70 52 M 5 930 140/100 Y 91 N 86 N 38 Y 140 N 191 N 122 N 5 Y 2 
71 42 F 5 593 112/70 N 77 N 75 N 52 N 136 N 185 N 116 N 3.5 N 0 
72 26 M 5 540 106/80 N 82 N 82 N 35 Y 142 N 192 N 119 N 5.4 Y 1 
73 54 M 5 200 156/90 Y 94 N 93 Y 36 Y 164 Y 234 Y 138 Y 6.5 Y 4 
74 39 M 5 284 120/82 N 
110/ 
KDM Y 88 N 32 Y 168 Y 210 Y 126 N 6.5 Y 3 
75 38 M 5 769 116/80 N 85 N 82 N 44 N 135 N 184 N 122 N 4.1 N 0 
76 20 F 5 568 100/70 N 75 N 75 N 54 N 132 N 174 N 114 N 3.2 N 0 
77 40 M 5 743 120/74 N 84 N 91 Y 38 Y 162 Y 194 N 138 Y 5.1 Y 3 
78 40 M 5 475 136/90 Y 92 N 85 N 35 Y 138 N 182 N 125 N 5.2 Y 2 
79 48 F 5 832 140/90 Y 
 98/  
KDM Y 82 Y 46 Y 155 Y 214 Y 142 Y 4.6 N 5 
80 36 M 5 341 110/70 N 76 N 82 N 48 N 122 N 184 N 133 N 3.8 N 0 
81 44 M 3 874 106/70 N 82 N 83 N 45 N 110 N 184 N 112 N 4 N 0 
82 47 M 5 373 120/80 N 89 N 94 Y 37 Y 224 Y 267 Y 141 Y 7.2 Y 3 
83 55 F 5 566 
140/80/
HT Y 92 N 86 Y 44 Y 172 Y 223 Y 135 Y 5 Y 4 
84 33 M 4 331 110/76 N 84 N 78 N 38 Y 131 N 184 N 104 N 4.8 N 1 
85 40 M 5 285 120/80 N 104 Y 93 Y 42 N 142 N 172 N 126 N 4 N 2 
86 36 M 3 516 100/72 N 83 N 82 N 46 N 135 N 181 N 114 N 3.9 N 0 
87 38 F 4 1360 120/70 N 88 N 78 N 47 Y 141 N 172 N 110 N 3.6 N 1 
88 42 M 5 1225 140/90 Y 92 N 87 N 38 Y 128 N 190 N 125 N 5 Y 2 
89 54 M 6 703 120/80 N 108 Y 86 N 36 Y 167 Y 228 Y 149 Y 6.3 Y 3 
90 42 M 5 325 116/82 N 92 N 85 N 45 N 210 Y 184 N 136 Y 4 N 1 
91 54 F 6 322 140/90 Y 95 N 86 Y 44 Y 172 Y 198 N 126 N 4.5 N 4 
92 55 M 6 121 140/86 Y 
102/ 
KDM Y 94 Y 36 Y 168 Y 245 Y 141 Y 6.8 Y 5 
93 45 F 5 614 110/80 N 116 Y 87 Y 42 Y 140 N 191 N 114 N 4.5 N 3 
94 31 M 4 609 110/70 N 88 N 81 N 48 N 134 N 189 N 117 N 3.9 N 0 
95 35 F 5 598 120/82 N 76 N 83 Y 47 Y 136 N 182 N 110 N 3.8 N 2 
96 48 M 5 103 128/80 N 104 Y 94 Y 35 Y 182 Y 235 Y 152 Y 6.7 Y 4 
97 31 F 3 609 100/70 N 82 N 72 N 52 N 130 N 172 N 105 N 3.3 N 0 
98 45 M 4 760 140/92 Y 79 N 93 Y 34 Y 142 N 190 N 124 N 5.5 Y 3 
99 40 M 3 266 126/84 N 84 N 85 N 38 Y 152 Y 194 N 114 N 5.1 Y 2 
## 42 M 5 577 110/80 N 74 N 81 N 35 Y 144 N 180 N 123 N 5.1 Y 1 
 
 
 
 
 
 
 
 
 
Abbreviations: 
ART D    - Anti retroviral therapy duration 
Y            - Yes 
N           - No 
BP         - Blood pressure 
KHT       - known hypertensive 
FBS       - Fasting blood sugar 
KDM     - known diabetes mellitus 
AC         - Abdominal circumference 
TGL       - triglycerides 
HDL      - High density lipoprotein 
TC         - total cholesterol 
LDL       - low density lipoprotein 
MS        - Metabolic syndrome 
 
 
 
 
